此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

一项为期 48 个月的研究,旨在评估 Elocta 对关节健康的长期疗效 (A-MORE)

2026年9月18日 更新者:Swedish Orphan Biovitrum

一项为期 48 个月的多中心观察性研究,旨在评估 Elocta 对关节健康的长期疗效

This is a 48-month observational, prospective, multicentre study. The overall aim of the study is to evaluate the long-term effectiveness of Elocta treatment on joint health in patients treated prophylactically with Elocta in a real-world setting.

研究概览

地位

完全的

干预/治疗

详细说明

Haemophilia A is a rare genetic disorder estimated to occur in one out of 10,000 live births, characterized by a deficiency in coagulation factor VIII causing impaired haemostasis and prolonged bleeding episodes. Moderate haemophilia, defined as < 5%, and severe haemophilia, defined as < 1% of normal factor VIII activity result in frequent and spontaneous bleeds into muscles and joints, commonly the elbows, knees, and ankles. Bleeding into joints can cause acute pain and swelling and can result in reduced joint range of motion, long-term cartilage damage and debilitating haemophilic arthropathy. Early use of prophylaxis with factor VIII replacement is recommended following diagnosis of haemophilia A to maintain joint health and prevent joint destruction. However, despite the use of prophylaxis many patients still experience joint bleeds which may lead to joint deterioration over time. The risk of joint bleeds increases with the amount of time spent below certain FVIII trough levels, e.g. 1, 3 or 5 IU/dL. Thus, there is probably a relation between the intensity of the prophylactic treatment regimen and joint health. Elocta is an extended half-life rFVIII product (EHL rFVIII), with a slower clearance as compared to conventional FVIII products. Treatment with Elocta will therefore provide the treater with a greater flexibility for individualizing prophylaxis as compared to conventional FVIII. Higher trough levels can be reached with Elocta without increasing factor usage or injection frequency. The treater can instead choose to reduce the injection frequency or the factor consumption without lowering trough levels.

Patients may limit their physical activities due to fear of bleeding if they are unaware of their current FVIII level. Patient apps and wearables are now available which allow patients to view their predicted FVIII levels, and capture health-related data (such as bleedings, pain, well-being, physical activity levels etc.). This data can be shared with the treating physician supporting the planning to individualize the patient's factor treatment based on current lifestyle, health status and physical activity levels. Florio, a certified medical device used as part of routine clinical practice, is such an app, and the data output and patient feedback on their activity levels and sense of protection while using Florio will be analysed as exploratory objectives in this study.

The main purpose of this study is to evaluate the effectiveness of Elocta on joint health over a long observation period (48 months). The study will also explore the influence on long term joint health of different Elocta prophylaxis regimens leading to different trough levels and if the extent of patients' physical activity levels can be associated with predicted FVIII levels.

研究类型

观察性的

注册 (实际的)

427

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Thessaloniki、希腊
        • Ippokrateio Hospital Thessaloniki (adult department)
      • Thessaloniki、希腊
        • Ippokrateio Hospital Thessaloniki (pediatric department)
      • Berlin、德国
        • Charité-Universitätsmedizin Berlin Campus Virchow Klinikum
      • Bonn、德国
        • Universitätsklinikum Bonn AöR, Institut für Experimentelle Hämatologie und Transfusionsmedizin
      • Frankfurt、德国
        • Hämostaseologie/Hämophiliezentrum, Medizinische Klinik 2 Institut für Transfusionsmedizin, Universitätsklinikum
      • Frankfurt、德国
        • Universitätsklinikum Frankfurt - Klinik für Kinder- und Jugendmedizin
      • Hamburg、德国
        • Universitätsklinikum Hamburg-Eppendorf (UKE)
      • Hanover、德国
        • Medizinische Hochschule Hannover
      • Hanover、德国
        • Werlhof-Institut für Hämostaseologie GmbH
      • Heidelberg、德国
        • SRH-Klinikum Heidelberg
      • Mörfelden-Walldorf、德国
        • HZRM Hämöphilie Zentrum Rhein Main
      • München、德国
        • Kinderklinik und Kinderpoliklinik im Dr. von Haunerschen Kinderspital am Universitätsklinikum München
      • Bari、意大利
        • University of Bari Aldo Moro (Centro Emofilia Policlinico - Pediatria U.O.)
      • Cesena、意大利
        • AUSL Romagna Centro Emofilia U.O.C., Medicina Trasfusionale Dipartimento Patologia, Clinica Ospedale M. Bufalini
      • Genova、意大利
        • Giannina Gaslini Institute
      • Milan、意大利
        • Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
      • Parma、意大利
        • University Hospital of Parma, AOUP, Haemophilia Center
      • Rome、意大利
        • Uo Malattie Emorragiche e Trombotiche Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Universitá Catolica del Sacro Coure
      • Torino、意大利
        • Azienda Ospedaliera Città della Salute e della Scienza di Torino Regina Margherita
      • Brno、捷克语
        • University Hospital Brno
      • Ostrava、捷克语
        • University Hospital Ostrava
      • Prague、捷克语
        • Dept. of Pediatric Haematology and Oncology, University Hospital Motol
      • Ljubljana、斯洛文尼亚
        • University Medical Centre Ljubljana Division of Paediatrics
      • Riyadh、沙特阿拉伯
        • Dr Suliman Al Habib Hospital Riyadh
      • Riyadh、沙特阿拉伯
        • King Faisal Specialised Hospital, KFSH Riyadh, Children
      • Riyadh、沙特阿拉伯
        • King Faisal Specialist Hospital KFSH, Adults
      • Riyadh、沙特阿拉伯
        • Riyadh Military Hospital (P.S.M.C)
      • Tallinn、爱沙尼亚
        • Lastehaigla, Tallinn (Tallinn Children´s Hospital)
      • Tallinn、爱沙尼亚
        • The North Estonia Medical Centre Hematoloogiakeskus, Regionalhaigla
      • Gothenburg、瑞典
        • Hematologimottagning Sahlgrenska
      • Malmö、瑞典
        • Department of Haematology, Oncology and Radiation Physics, Skåne University Hospital Malmö
      • Bern、瑞士
        • Universitätsklinik für Hämatologie und Hämatologisches Zentrallabor Inselspital
      • Lausanne、瑞士
        • Service et Laboratoire central d'hématologie, Adults
      • Sankt Gallen、瑞士
        • Zentrum für Labormedizin
      • Zurich、瑞士
        • Universitätsspital Zürich Klinik für Medizinische Onkologie und Hämatologie
      • Helsinki、芬兰
        • Helsinki University Central Hospital, New Children Hospital
      • Turku、芬兰
        • Turku University Central Hospital, Paediatric and adolescent haematology and oncology clinic
      • Canterbury、英国
        • East Kent Hospitals University NHS Foundation Trust, Kent Haemophilia and Thrombosis Centre, Kent and Canterbury Hospital
      • London、英国
        • Great Ormond Street Hospital, Royal London Hospital for Integrated Medicine
      • Groningen、荷兰
        • University Medical Center Groningen/UMCG
      • Barcelona、西班牙
        • Sant Johan De Deu
      • Barcelona、西班牙
        • Hospital de la Santa Creu i Sant Pau
      • Barcelona、西班牙
        • Hospital Vall d'Hebron
      • Cruces、西班牙
        • Hospital Universitario Cruces
      • Donostia / San Sebastian、西班牙
        • Hospital Universitario Donostia
      • Murcia、西班牙
        • Hospital Virgen de la Arrixaca
      • Málaga、西班牙
        • Hospital Universitario Carlos Haya
      • Navarro、西班牙
        • Complejo Hospitalario de Navarra
      • Oviedo、西班牙
        • Hospital Universitario Central de Asturias (HUCA)
      • Palma de Mallorca、西班牙
        • Hospital Universitario Son Espases
      • Seville、西班牙
        • Hospital Universitario Virgen del Rocío
      • Vigo、西班牙
        • Hospital Alvaro Cunqueiro
      • Muscat、阿曼
        • The Royal Hospital

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 孩子
  • 成人
  • 年长者

接受健康志愿者

不

有资格学习的性别

全部

取样方法

非概率样本

研究人群

Patients diagnosed with haemophilia A regardless of severity, of any gender and age, on factor treatment with Elocta according to usual clinical practice.

描述

Inclusion Criteria:

  • Provided signed and dated informed consent by the patient, or the patient's legally authorized representative(s) for patients under the legal age, before any study-related activities are undertaken. Assent should be obtained from paediatric patients according to local regulations
  • Have a diagnosis of haemophilia A
  • At enrolment on prophylactic treatment with Elocta, independent of participation in the study

Exclusion Criteria:

  • Enrolment in another concurrent clinical interventional study, or intake of an Investigational Medicinal Product (IMP), within three months prior to inclusion in this study
  • Presence of factor VIII antibodies (inhibitors) (≥0.60 Bethesda Unit [BU]/mL) at the latest available inhibitor test

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:COHORT
  • 时间观点:PROSPECTIVE

队列和干预

团体/队列
干预/治疗
Hemophilia A patients

All patients diagnosed with haemophilia A regardless of severity, on factor treatment with Elocta according to usual clinical practice.

Extended half-life factor VIII product

其他名称:
  • efmoroctocog alfa
  • 定位
  • rFVIIIFc

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Joint health: Target joint development
大体时间:48 months

Number of target joints

48 months
Joint health: Target joint resolution
大体时间:48 months

Number of resolved target joints

48 months
Joint health: Target joint recurrence
大体时间:48 months

Number of recurring target joints

48 months
Joint health: Annualised joint bleeding rate (AJBR) for treated bleeds
大体时间:48 months

Number of joint bleeding events per year, for treated bleeds

48 months

次要结果测量

结果测量
措施说明
大体时间
Disease Activity (hypertrophic synovium) and Disease Damage (Cartilage or Bone) scores for elbows, knees and ankles
大体时间:48 months

The Haemophilia Early Arthropathy Detection with UltraSound (HEAD-US) protocol will be used. The total score represents the sum of item scores for abnormalities detected. Its values range from 0 (minimum) to 8 (maximum). A higher score indicates a worse outcome.

48 months
Global Gait Score, and/or joint score items for elbows, knees and ankles.
大体时间:48 months

The Haemophilia Joint Health Score (HJHS) system will be used. Global Gait Score, and/or Joint score items (swelling, duration of swelling, muscle atrophy, axial alignment, crepitus on motion, flexion loss, instability, extension loss, joint pain, strength, gait) for elbows, knees and ankles.

The minimum score per joint is 0, the maximum score is 20. The overall total joint score (range 0-120) is the sum of the 6 six index joint (elbows, knees and ankles) scores. A higher score indicates a worse outcome.

48 months
Joint and physical evaluation for elbows, knees and ankles.
大体时间:48 months

The WFH Physical Examination Score (AKA Gilbert Score) will be used. Joint evaluation (pain, bleeding, physical examination and radiologic evaluation) and physical evaluation (swelling, muscle atrophy, axial deformity, crepitus on motion, range of motion, flexion contracture, and instability). A higher score indicates a worse outcome.

48 months

其他结果措施

结果测量
措施说明
大体时间
Effectiveness of Elocta: Annualised bleeding rate (ABR) for treated bleeds
大体时间:48 months

Number of bleeding events per year, for treated bleeds

48 months
Effectiveness of Elocta: Annualised bleeding rate (ABR) for all bleeds
大体时间:48 months

Number of bleeding events per year, for all bleeds

48 months
Effectiveness of Elocta: Occurrence of zero (0) joint bleeds
大体时间:48 months

Percentage (%) of study population with zero (0) joint bleeds

48 months
Effectiveness of Elocta: Work productivity and impairment
大体时间:48 months

Assessed by WPAI-SHP questionnaire

48 months
Effectiveness of Elocta: Quality of Life
大体时间:48 months

Assessed by Haemo-QoL/Haem-A-QoL questionnaire

48 months
Effectiveness of Elocta: Physical activity level
大体时间:48 months

Assessed by the Saltin-Grimby scale

48 months
Effectiveness of Elocta: Quality of Life
大体时间:48 months

Assessed by EQ-5D-5L/EQ-5D-Y questionnaire

48 months
Effectiveness of Elocta: Severity of joint health
大体时间:48 months

Assessed by Patient Global Impression of Severity of Joint Health questionnaire

48 months
Effectiveness of Elocta: FVIII plasma levels
大体时间:48 months

Percentage (%) of FVIII plasma level

48 months
Effectiveness of Elocta: Usage of pain and anti-inflammatory medication
大体时间:48 months

Assessed by medication dose

48 months
Effectiveness of Elocta: Usage of pain and anti-inflammatory medication
大体时间:48 months

Assessed by total number of exposure days per medication

48 months
Usage of Elocta: Annualised injection frequency per subject
大体时间:48 months

Assessed by prescription

48 months
Usage of Elocta: Annualised factor consumption per subject
大体时间:48 months

Assessed by prescription [IU/kg]

48 months
Usage of Elocta: Adherence
大体时间:48 months

Investigator assessed (Percentage (%))

48 months
Exploratory Objective
大体时间:48 months

Influence of different Elocta prophylaxis regimens on long term joint health

48 months
Exploratory Objective: Impact of florio HAEMO on patients' sense of protection and their activity level
大体时间:48 months

Results from questionnaire on impact of florio HAEMO tools on patients' sense of protection and their activity level

48 months
Exploratory Objective: Explore adherence to prescribed treatment regimen
大体时间:48 months

florio HAEMO captured treatment adherence scores

48 months
Exploratory Objective: Explore relationship between predicted FVIII levels and physical activity
大体时间:48 months

florio HAEMO captured predicted FVIII levels, florio HAEMO captured physical activity (type, duration, heart rate and steps)

48 months
Exploratory Objective: Explore timing of bleeds in relation to predicted FVIII levels and physical activity
大体时间:48 months

florio HAEMO captured bleed data (timing, location, cause, treated/untreated), florio HAEMO captured injection data (time, dose), florio HAEMO captured predicted FVIII levels

48 months
Exploratory Objective: Explore the use of Florio to characterise pain and well-being
大体时间:48 months

florio HAEMO captured pain data (time, location, cause, intensity), florio HAEMO captured well-being data

48 months
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
大体时间:48 months

Target joint development, resolution and recurrence

48 months
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
大体时间:48 months

Annualised joint bleeding rate (AJBR) for treated bleeds

48 months
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
大体时间:48 months

Ultrasound (HEAD-US)

48 months
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
大体时间:48 months

Clinical joint scoring (HJHS)

48 months
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
大体时间:48 months

Annualised bleeding rate (ABR) (based on bleeding episodes assessed according to local practice) for all bleeds

48 months
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
大体时间:48 months

Occurrence of zero (0) joint bleeds

48 months
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
大体时间:48 months

Quality of Life assessed by Haemo-QoL/Haem-A-QoL

48 months
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
大体时间:48 months

Physical activity level assessed by the Saltin-Grimby scale

48 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:Study Physician、Swedish Orphan Biovitrum

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2020年3月30日

初级完成 (实际的)

2026年5月4日

研究完成 (实际的)

2026年5月4日

研究注册日期

首次提交

2020年2月20日

首先提交符合 QC 标准的

2020年3月2日

首次发布 (实际的)

2020年3月3日

研究记录更新

最后更新发布 (实际的)

2026年9月22日

上次提交的符合 QC 标准的更新

2026年9月18日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅